Marché mondial de la transplantation d’organes solides – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché de la transplantation d'organes solides

Le marché mondial de la transplantation d'organes solides devrait connaître une croissance significative au cours de la période de prévision. La demande croissante de nouveaux produits de transplantation de tissus et de transplantation d'organes pour le traitement de la défaillance d'organes est l'un des principaux facteurs de croissance du marché. Les mauvaises habitudes alimentaires, le manque d'exercice, la consommation d'alcool et la toxicomanie sont quelques-unes des causes importantes de la défaillance d'organes. Il a été constaté que les produits tissulaires étaient le segment générant le plus de revenus en 2021, avec une part de marché de 57,8 %. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

Data Bridge Market Research analyse le taux de croissance du marché mondial de la transplantation d'organes solides au cours de la période de prévision 2022-2029. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Définition du marché

La transplantation d'organes solides est un avantage pour les patients souffrant de maladies rénales, pancréatiques, de l'intestin grêle, du cœur, du foie et des poumons en phase terminale. Bien qu'il ne s'agisse pas d'un processus qui améliore la survie, certaines améliorations de la qualité de vie sont obtenues grâce à l'allogreffe composite vasculaire et à la transplantation d'utérus. Elle revêt une grande importance pour le secteur de la santé et devrait donc connaître une forte croissance au cours de la période de prévision.

Portée et segmentation du marché de la transplantation d'organes solides

Global Solid Organ Transplantation Market Dynamics

Drivers

• Growing Demand for Organ Transplant

The global rise in the organ transplant demand can be attributed to an increase in the occurrence of acute diseases, which in turn leads to an increase in the number of organ failures. For instance, diabetes and high blood pressure are considered to be the most common causes of end-stage renal disease, wherein kidney transplants or dialysis are the only treatment options to keep a patient alive. As per the records of the U.S. Department of Health & Human Services, about 122,913 patients in the U.S. were waiting to receive organs for transplant in 2019. Thus, the demand for advanced transplantation products for the treatment of organ failure is high.This boosts the market growth.

• Technological Advancements

Several technological advancemnets in this sector are expected to boost the growth of the market. For instance, in September 2015, Arthrex Inc. launched ArthroFlex Acellular Dermal Matrix, a new orthobiologic product proposed for use in capsular reconstruction. This product allows preservation of its growth factors and native collagen scaffold and elastin and permits transplant to be successfully incorporated into the recipient. All these factors boost the market growth.

Opportunities

• Higher Mergers and Acquisitions

Several manufacturers are aiming on new product development, mergers & acquisition, and collaborations to enlarge their current product portfolio and maintain their persistent position in the market. For instance, in September 2016, Stryker Corporation announced the acquisition of Instratek. It is a top manufacturer of minimally invasive soft tissue recession instruments for ankle, foot, and upper extremity procedures.

• Increasing Sales of Immunosuppressive Drugs

Tissue products for transplantation accounted for the largest share in 2021, and this category is projected to maintain its position in the upcoming future due to the increasing use of orthobiologics in orthopedic procedures for normal functioning restoration, tissue healing, and pain minimization, combined with the increasing elderly population across the globe. Moreover, startup companies in this field are receiving investments to expand their business. Thus, this factor is creating much opportunities for the market growth.

Restraints/Challenges

• High Cost

The huge association with organ transplantation and many other immunosuppressive drugs restrain the market growth.

• Unavailability of Treatment

Not all the treatments are available in all the countries which restrict the market growth. There are several underdeveloped countries wherein the modified treatments are not available.  Thus, it restricts the growth of the market.

This global solid organ transplantation market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global solid organ transplantation market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Solid Organ Transplantation Market       

There has been a significant proportion of coronavirus patients who were hospitalized in medical centers, governing bodies were bound to restrict to these patients. The pandemic also caused a drip in organ transplant surgery enrolment globally.

The reduction in the number of transplantation and organ donation procedures is mostly because of factors such as engaged surgeons, unavailability of resources, lockdown, and travel restrictions. Patients having positive reports for COVID-19 were restricted from donating organs because of the possibility of infection. Additionally, another major concern prompting transplantation operations was the possibility of immunosuppressant drug interactions with COVID-19 therapy agents, which had led to a substantial number of organ failures from graft donors.  

Recent Development:

• In November 2020, Lupin launched a generic immunosuppressant drug, Tacrolimus in the U.S. market which is indicated for prophylaxis of organ rejection in the allogeneic liver, kidney, and heart transplant.

Global Solid Organ Transplantation Market Scope

The global solid organ transplantation market  is segmented on the basis of organ, product, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Organ

• Kidney
• Liver
• Pancreas
• Heart
• Lung
• Small Bowel
•  Kidney/Pancreas
•  Others

Product

• Tissue Products
• Immunosuppressive Drugs
• Preservation Solution

Treatment

• Immunosuppressive
• Monoclonal Antibodies
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Solid Organ Transplantation Market Regional Analysis/Insights

The global solid organ transplantation market  is analysed and market size insights and trends are provided by organ, product, treatment, distribution channel and end-user as referenced above.

The major countries covered in the global solid organ transplantation market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacture of the product and increased healthcare and R & D expenditure.

Asia-Pacific dominates the market due to increased prevalence of organ failure, and presence of generic drugs manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Solid Organ Transplantation Market Share Analysis

The global solid organ transplantation market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global solid organ transplantation market.

Les principaux acteurs opérant sur le marché mondial de la transplantation d’organes solides comprennent :

• Teva Pharmaceutical Industries Ltd (Israël)
• Mylan NV (États-Unis)
• Johnsons & Johnsons Services Inc (États-Unis)
• F. Hoffman-La Roche SA (Suisse)
• Lilly (États-Unis)
• Merck & Co., Inc. (États-Unis)
• Aurobindo Pharma (Inde)
• Société Bristol-Myers Squibb (États-Unis)
• GSK plc (Royaume-Uni)
• Ascendis Pharma A/S (Danemark)
• LEO Pharma A/S (Danemark)
• Genentech, Inc (États-Unis)
• Celltrion Inc (Corée du Sud)

SKU-54394